Cargando…

Antidiabetic Activity of Extracts of Terminalia brownii Fresen. Stem Bark in Mice

BACKGROUND: Diabetes mellitus is a chronic metabolic disorder that imposes a huge health and economic burden on societies. Because the currently available medications have many drawbacks, it is important to search for alternative therapies. Medicinal plants used in traditional medicines are ideal ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Alema, Niguse Meles, Periasamy, Gomathi, Sibhat, Gereziher Gebremedhin, Tekulu, Gebretsadkan Hintsa, Hiben, Mebrahtom Gebrelibanos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039073/
https://www.ncbi.nlm.nih.gov/pubmed/32110120
http://dx.doi.org/10.2147/JEP.S240266
_version_ 1783500754673205248
author Alema, Niguse Meles
Periasamy, Gomathi
Sibhat, Gereziher Gebremedhin
Tekulu, Gebretsadkan Hintsa
Hiben, Mebrahtom Gebrelibanos
author_facet Alema, Niguse Meles
Periasamy, Gomathi
Sibhat, Gereziher Gebremedhin
Tekulu, Gebretsadkan Hintsa
Hiben, Mebrahtom Gebrelibanos
author_sort Alema, Niguse Meles
collection PubMed
description BACKGROUND: Diabetes mellitus is a chronic metabolic disorder that imposes a huge health and economic burden on societies. Because the currently available medications have many drawbacks, it is important to search for alternative therapies. Medicinal plants used in traditional medicines are ideal candidates. Hence, this study was undertaken to investigate the antidiabetic activity of crude extract and solvent fractions from the stem bark of Terminalia brownii Fresen. (Combretaceae) in mice. MATERIALS AND METHODS: The in vitro α-amylase inhibition assay was performed using the chromogenic 3, 5-dinitrosalicylic acid (DNSA) method while the antihyperglycemic activity was assessed using three mouse models: streptozotocin-induced diabetic mice, normoglycemic mice, and oral glucose challenged mice. Experimental diabetes was induced by a single intraperitoneal injection of streptozotocin at a dose of 150 mg/kg and animals with fasting blood glucose level (BGL) >200 mg/dL were considered diabetic. Glibenclamide (5 mg/kg) was used as a standard drug. Fasting BGL and body weight were used to assess the antidiabetic activity. The result was analyzed using GraphPad Prism software version 8 and one-way ANOVA followed by Tukey’s post hoc test with p<0.05 considered as statistically significant. RESULTS: The crude extract of T. brownii at all tested dose levels (250, 500 and 750 mg/kg) showed a significant BGL reduction in all the three animal models. Moreover, the ethyl acetate and aqueous fractions (at 500 mg/kg) significantly (p<0.01) reduced the BGL in the streptozotocin induced diabetic model. The crude extract and different solvent fractions also showed a dose-dependent in vitro α-amylase inhibitory activity and improvement of body weight. CONCLUSION: T. brownii crude extract and its solvent fractions showed a significant antihyperglycemic activity in STZ induced diabetic mice, hypoglycemic activity and improvement of oral glucose tolerance in normal mice.
format Online
Article
Text
id pubmed-7039073
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-70390732020-02-27 Antidiabetic Activity of Extracts of Terminalia brownii Fresen. Stem Bark in Mice Alema, Niguse Meles Periasamy, Gomathi Sibhat, Gereziher Gebremedhin Tekulu, Gebretsadkan Hintsa Hiben, Mebrahtom Gebrelibanos J Exp Pharmacol Original Research BACKGROUND: Diabetes mellitus is a chronic metabolic disorder that imposes a huge health and economic burden on societies. Because the currently available medications have many drawbacks, it is important to search for alternative therapies. Medicinal plants used in traditional medicines are ideal candidates. Hence, this study was undertaken to investigate the antidiabetic activity of crude extract and solvent fractions from the stem bark of Terminalia brownii Fresen. (Combretaceae) in mice. MATERIALS AND METHODS: The in vitro α-amylase inhibition assay was performed using the chromogenic 3, 5-dinitrosalicylic acid (DNSA) method while the antihyperglycemic activity was assessed using three mouse models: streptozotocin-induced diabetic mice, normoglycemic mice, and oral glucose challenged mice. Experimental diabetes was induced by a single intraperitoneal injection of streptozotocin at a dose of 150 mg/kg and animals with fasting blood glucose level (BGL) >200 mg/dL were considered diabetic. Glibenclamide (5 mg/kg) was used as a standard drug. Fasting BGL and body weight were used to assess the antidiabetic activity. The result was analyzed using GraphPad Prism software version 8 and one-way ANOVA followed by Tukey’s post hoc test with p<0.05 considered as statistically significant. RESULTS: The crude extract of T. brownii at all tested dose levels (250, 500 and 750 mg/kg) showed a significant BGL reduction in all the three animal models. Moreover, the ethyl acetate and aqueous fractions (at 500 mg/kg) significantly (p<0.01) reduced the BGL in the streptozotocin induced diabetic model. The crude extract and different solvent fractions also showed a dose-dependent in vitro α-amylase inhibitory activity and improvement of body weight. CONCLUSION: T. brownii crude extract and its solvent fractions showed a significant antihyperglycemic activity in STZ induced diabetic mice, hypoglycemic activity and improvement of oral glucose tolerance in normal mice. Dove 2020-02-20 /pmc/articles/PMC7039073/ /pubmed/32110120 http://dx.doi.org/10.2147/JEP.S240266 Text en © 2020 Alema et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Alema, Niguse Meles
Periasamy, Gomathi
Sibhat, Gereziher Gebremedhin
Tekulu, Gebretsadkan Hintsa
Hiben, Mebrahtom Gebrelibanos
Antidiabetic Activity of Extracts of Terminalia brownii Fresen. Stem Bark in Mice
title Antidiabetic Activity of Extracts of Terminalia brownii Fresen. Stem Bark in Mice
title_full Antidiabetic Activity of Extracts of Terminalia brownii Fresen. Stem Bark in Mice
title_fullStr Antidiabetic Activity of Extracts of Terminalia brownii Fresen. Stem Bark in Mice
title_full_unstemmed Antidiabetic Activity of Extracts of Terminalia brownii Fresen. Stem Bark in Mice
title_short Antidiabetic Activity of Extracts of Terminalia brownii Fresen. Stem Bark in Mice
title_sort antidiabetic activity of extracts of terminalia brownii fresen. stem bark in mice
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039073/
https://www.ncbi.nlm.nih.gov/pubmed/32110120
http://dx.doi.org/10.2147/JEP.S240266
work_keys_str_mv AT alemanigusemeles antidiabeticactivityofextractsofterminaliabrowniifresenstembarkinmice
AT periasamygomathi antidiabeticactivityofextractsofterminaliabrowniifresenstembarkinmice
AT sibhatgerezihergebremedhin antidiabeticactivityofextractsofterminaliabrowniifresenstembarkinmice
AT tekulugebretsadkanhintsa antidiabeticactivityofextractsofterminaliabrowniifresenstembarkinmice
AT hibenmebrahtomgebrelibanos antidiabeticactivityofextractsofterminaliabrowniifresenstembarkinmice